Review
Copyright ©The Author(s) 2022.
World J Gastrointest Pathophysiol. Jan 22, 2022; 13(1): 15-33
Published online Jan 22, 2022. doi: 10.4291/wjgp.v13.i1.15
Table 2 Studies on neoadjuvant imatinib therapy for gastrointestinal stromal tumors
Ref.
Clinical trial
Yr
Design
Endpoint
Cases
Agent/Dose
Patients
Duration
RR
R0 rate
Adjuvant imatinib
PFS
OS
Prospective study
Eisenberg et al[39]RTOG0132 trial2009Phase IIRFS30 (all; 52)Imatinib/600 mgGIST (> 5 cm)8-12 wk7%77%24 mo2-yr PFS; 83%2-yr OS; 93%
Wang et al[40]RTOG0132 (long follow up)201231 (all; 53)5-yr PFS; 57%5-yr OS; 77%
Doyon et al[41]2012Phase IIRR14Imatinib/400 mgLocally advanced GIST6 mo43%79%12 mo4-yr DFS; 64%4-yr OS; 100%
Kurokawa et al[42]Asia2017Phase IIPFS53Imatinib/400 mgGastric GIST (> 10 cm)6-9 mo62%91%36 mo2-yr PFS; 89%2-yr OS; 98%
Retrospective study
Blesius et al[35]BFR14 trial2011Subset phase III-25Imatinib/400 mgLocally advanced GIST4.2 mo (median)60%32%13-24 mo3-yr PFS; 67%3-yr OS; 89%
Rutkowski et al[36]EORTC2012Database-161Imatinib/400 mgLocally advanced GIST40 wk (median)80%83%At least 1 yr (56%)5-yr DFS; 65% 5-yr DSS; 95%
Tielen et al[37]2013DatabasePFS/OS57Imatinib/400 mgGIST (> 5 cm) and/or ill-located for surgery8 mo (median)83%84%1, 2 yr or lifelong (58%)5-yr PFS; 77%5-yr OS; 88%